



Conference Learning Objectives

- Analyze the latest advancements in cardiovascular and metabolic disease
- Interpret and apply current cardiovascular guidelines
- Evaluate clinical trial results and their impact on patient care

Conference Date & Time

SESSION 1 Wednesday, June 4th
(6:45 - 9:15 pm EDT)

SESSION 2 Wednesday, June 11th
(6:45 - 9:15 pm EDT)

SESSION 3 Wednesday, June 18th
(6:45 - 9:15 pm EDT)

Conference Co-Chairs



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
Assistant Professor, Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network Brampton, ON



Megha Poddar

MD, FRCPC, ABOM
Clinical Director, LMC Weight Management Centre
Assistant Clinical Professor (Adjunct), McMaster University

Certified Program Agenda

Faculty

SESSION 1: Wednesday, June 4th (6:45 - 9:15 pm EDT)

- 7:10 PM **Welcome and Introductions** Milan Gupta
- 7:20 PM Wearable technology in healthcare: Friend or foe? Arun Sridhar
- 7:40 PM Diabetes update: What's new in the 2024 guidelines? Sonia Butalia
- 8:00 PM The patient with CKD: Which drugs and when? Rita Suri
- 8:20 PM Common pitfalls in anticoagulation for atrial fibrillation Jason Andrade
- 8:40 PM Q&A
- 9:10 PM **Closing Comments**

SESSION 2: Wednesday, June 11th (6:45 - 9:15 pm EDT)

- 7:10 PM **Welcome and Introductions** Milan Gupta
- 7:20 PM Applying lipid guidelines in primary prevention Liam Brunham
- 7:40 PM Lipid management of the post-MI patient Milan Gupta
- 8:00 PM The patient with elevated Lp(a): What to do? Iulia Iatan
- 8:20 PM What's in the pipeline in lipid management? Deepak Bhatt
- 8:40 PM Q&A
- 9:10 PM **Closing Comments**

SESSION 3: Wednesday, June 18th (6:45 - 9:15 pm EDT)



- 7:10 PM **Welcome and Introductions** Milan Gupta
- 7:20 PM How to diagnose and treat HFpEF in primary care Stephanie Poon
- 7:40 PM Challenges in treating HFrEF in primary care Peter Liu
- 8:00 PM GLP-1-based treatments for cardiovascular disease Kim Connelly
- 8:20 PM What's in the pipeline for obesity management? Megha Poddar
- 8:40 PM Q&A
- 9:10 PM **Closing Comments**



Register Now →

Visit at: www.ccrnmd.com

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, Ultragenyx
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim

For inquiries regarding this program,
please contact info@ccrnmd.com



Program Agenda


Time	Topic	Learning Objective	Faculty
SESSION 1: Wednesday, June 4th (6:45 - 9:15 pm EDT)			
7:10 - 7:20 PM	Welcome and Introductions		Milan Gupta
7:20 - 7:40 PM	Wearable technology in healthcare: Friend or foe?	Evaluate the benefits and challenges of wearable technology in cardiovascular healthcare	Arun Sridhar
7:40 - 8:00 PM	Diabetes update: What's new in the 2024 guidelines?	Analyze the key updates in the 2024 diabetes guidelines and their implications for cardiovascular risk management and patient care.	Sonia Butalia
8:00 - 8:20 PM	The patient with CKD: Which drugs and when	Evaluate the role of SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone in the management of patients with chronic kidney disease (CKD) and cardiovascular risk.	Rita Suri
8:20 - 8:40 PM	Common pitfalls in anticoagulation for atrial fibrillation	Implement evidence-based strategies to optimize patient safety, adherence, and therapeutic outcomes for patients with atrial fibrillation	Jason Andrade
8:40 - 9:10 PM	Q&A		
9:10 - 9:15 PM	Closing Comments		
SESSION 2: Wednesday, June 11th (6:45 - 9:15 pm EDT)			
7:10 - 7:20 PM	Welcome and Introductions		Milan Gupta
7:20 - 7:40 PM	Applying lipid guidelines in primary prevention	Implement current lipid guidelines in primary prevention by assessing cardiovascular risk and optimizing lipid-lowering therapy for at-risk patients.	Liam Brunham
7:40 - 8:00 PM	Lipid management of the post-MI patient	Optimize lipid management and reduce recurrent cardiovascular events for post-MI patients.	Milan Gupta
8:00 - 8:20 PM	The patient with elevated Lp(a): What to do?	Develop evidence-based strategies for assessing and managing patients with elevated lipoprotein(a) [Lp(a)] to reduce cardiovascular risk.	Iulia Iatan



Register Now →

Visit at: www.ccrnmd.com

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, Ultragenyx
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim

For inquiries regarding this program, please contact info@ccrnmd.com



Program Agenda



Time	Topic	Learning Objective	Faculty
SESSION 2: Wednesday, June 11th (6:45 - 9:15 pm EDT)			
8:20 - 8:40 PM	What's in the pipeline in lipid management?	Explore emerging therapies and advancements in lipid management and their potential impact on cardiovascular risk reduction.	Deepak Bhatt
8:40 - 9:10 PM	Q&A		
9:10 - 9:15 PM	Closing Comments		
SESSION 3: Wednesday, June 18th (6:45 - 9:15 pm EDT)			
7:10 - 7:20 PM	Welcome and Introductions		Milan Gupta
7:20 - 7:40 PM	How to diagnose and treat HFpEF in primary care	Identify key clinical, diagnostic, and imaging criteria to accurately diagnose heart failure with preserved ejection fraction (HFpEF) in primary care.	Stephanie Poon
7:40 - 8:00 PM	Challenges in treating HFrEF in primary care	Implement effective strategies to optimize HFrEF management by primary care physicians	Peter Liu
8:00 - 8:20 PM	GLP-1-based treatments for cardiovascular disease	Implement effective risk reduction strategies for patients with obesity and cardiovascular disease to improve outcomes.	Kim Connelly
8:20 - 8:40 PM	What's in the pipeline for obesity management?	Examine emerging therapies and innovative approaches in obesity management and their potential impact on cardiovascular risk reduction.	Megha Poddar
8:40 - 9:10 PM	Q&A		
9:10 - 9:15 PM	Closing Comments		



Register Now →

Visit at: www.ccrnmd.com

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, Ultragenyx
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim

For inquiries regarding this program, please contact info@ccrnmd.com



Program Agenda

Conference Learning Objectives

- Analyze the latest advancements in cardiovascular and metabolic disease
- Interpret and apply current cardiovascular guidelines
- Evaluate clinical trial results and their impact on patient care

Conference Date & Time

SESSION 1

Wednesday, June 4th
(6:45 - 9:15 pm EDT)

SESSION 2

Wednesday, June 11th
(6:45 - 9:15 pm EDT)

SESSION 3

Wednesday, June 18th
(6:45 - 9:15 pm EDT)

Non-Certified Program Agenda

Faculty

SESSION 1: Wednesday, June 4th (6:45 - 7:10 pm EDT)

6:45 - 7:10 PM Learning Objectives - TBD TBD

This session is not certified by the College of Family Physicians of Canada.

SESSION 2: Wednesday, June 11th (6:45 - 7:10 pm EDT)

6:45 - 7:10 PM Learning Objectives - TBD TBD

This session is not certified by the College of Family Physicians of Canada.

SESSION 3: Wednesday, June 18th (6:45 - 7:10 pm EDT)

6:45 - 7:10 PM Learning Objectives - TBD TBD

This session is not certified by the College of Family Physicians of Canada.

Conference Co-Chairs



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
 Assistant Professor, Department of
 Medicine,
 University of Toronto
 Medical Director,
 Collaborative CME and Research
 Network Brampton, ON



Megha Poddar



MD, FRCPC, ABOM
 Clinical Director, LMC Weight
 Management Centre
 Assistant Clinical Professor
 (Adjunct), McMaster University



Register Now →

Visit at: www.ccrnmd.com

This program has received unrestricted
 educational funding support from:

 **Gold:** Amgen, Ultragenyx
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim

For inquiries regarding this program,
 please contact info@ccrnmd.com